Canaccord Genuity Reiterates a 'Buy' on Orexigen Therapeutics (OREX); Provides More Clarity on Contrave's Path Forward; Stock Has Room
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Orexigen Therapeutics (NASDAQ: OREX) and $19 price target.
Canaccord analyst says, "Following the positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Following the positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
